Acid ceramidase gene therapy
Acid ceramidase gene therapy has been studied in 2 papers since 2022: none in people yet, 2 in animals. The research so far is in animals. The newest paper, Aug 11, 2023: “Acid ceramidase gene therapy ameliorates pulmonary arterial hypertension with right heart dysfunction”.
2 papers study it8 findingsUpdated
None of its findings points the other way.
- 1 lab in 1 country
- Animals2
What did studies of Acid ceramidase gene therapy find?
4Studies of Acid ceramidase gene therapy measured 4 outcomes; the most studied are inflammation (2 studies), cellular senescence (2) and medial wall thickness (2).
Inflammation
downin Rodentia1downin rodents1
2 studies
Inflammation
downin Rodentia1downin rodents1
Acid ceramidase gene therapy decreases inflammation in Rodentia.
“After acid ceramidase gene delivery, a significant decrease of pro-inflammatory factors, interleukins, and senescence markers was observed.”
Animalspulmonary hypertension modelintratracheal administrationlung8 weeks
Respiratory research
Acid ceramidase gene therapy decreases inflammation in rodents.
“After acid ceramidase gene delivery, a significant decrease of pro-inflammatory factors, interleukins, and senescence markers was observed.”
Animalsin rodent PAH model (pneumonectomy + Sugen)8 weeks
Research SquarePreprint
Cellular senescence
downin Rodentia1downin rodents1
2 studies
Cellular senescence
downin Rodentia1downin rodents1
Acid ceramidase gene therapy decreases cellular senescence in Rodentia.
“After acid ceramidase gene delivery, a significant decrease of pro-inflammatory factors, interleukins, and senescence markers was observed.”
Animalspulmonary hypertension modelintratracheal administrationlung8 weeks
Respiratory research
Acid ceramidase gene therapy decreases cellular senescence in rodents.
“After acid ceramidase gene delivery, a significant decrease of pro-inflammatory factors, interleukins, and senescence markers was observed.”
Animalsin rodent PAH model (pneumonectomy + Sugen)8 weeks
Research SquarePreprint
Medial wall thickness
downin Rodentia1downin rodents1
2 studies
Medial wall thickness
downin Rodentia1downin rodents1
Acid ceramidase gene therapy decreases medial wall thickness in Rodentia.
“Morphometric analysis demonstrated an increase in medial wall thickness in control groups in comparison to those treated with acid ceramidase.”
Animalspulmonary hypertension modelintratracheal administrationpulmonary artery8 weeks
Respiratory research
Acid ceramidase gene therapy decreases medial wall thickness in rodents.
“Morphometric analysis demonstrated an increase in medial wall thickness in control groups in comparison to those treated with acid ceramidase.”
Animalsin rodent PAH model (pneumonectomy + Sugen)pulmonary artery8 weeks
Research SquarePreprint
Pulmonary vascular resistance
downin Rodentia1downin rodents1
2 studies
Pulmonary vascular resistance
downin Rodentia1downin rodents1
Acid ceramidase gene therapy decreases pulmonary vascular resistance in Rodentia (4.44 ± 0.71 mm Hg vs 6.79 ± 0.85 mm Hg).
“but not in animals receiving Anc80L65.AC (4.44 ± 0.71 mm Hg, p < 0.001).”
Animalspulmonary hypertension modelintratracheal administrationpulmonary artery8 weeks
Respiratory research
Acid ceramidase gene therapy decreases pulmonary vascular resistance in rodents (4.44 ± 0.71 mm Hg vs 6.79 ± 0.85 mm Hg (p < 0.001)).
“significant increase in pulmonary vascular resistance in the saline-treated (6.79 ± 0.85 mm Hg) and empty capsid (6.94 ± 0.47 mm Hg) groups, but not in animals receiving Anc80L65.AC (4.44 ± 0.71 mm Hg, p < 0.001)”
Animalsin rodent PAH model (pneumonectomy + Sugen)Anc80L65.AC8 weeks
Research SquarePreprint